BSTC

SC 13G/A - BIOSPECIFICS TECHNOLOGIES CORP (0000875622) (Subject)

SC 13G/A - BIOSPECIFICS TECHNOLOGIES CORP (0000875622) (Subject)

15-12B - BIOSPECIFICS TECHNOLOGIES CORP (0000875622) (Filer)

DUBLIN, Dec. 2, 2020 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that it completed the previously announced acquisition of BioSpecifics Technologies Corp., a commercial-stage biopharmaceutical company, for $88.50 per share in an all-cash transaction, for an estimated enterprise value of approximately $540 million (net of approximately $120 million in cash acquired). "We're pleased to have completed the acquisition of BioSpecifics, which immediately enhances our adjusted EBITDA and the profitability profile of both XIAFLEX® and Qwo™—two of our most durable and differentiated products with significant long-term growth potential," said Blaise Coleman, President and

DUBLIN, Nov. 18, 2020 /PRNewswire/ -- Endo International plc (Nasdaq: ENDP) ("Endo") today announced the expiration of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), in connection with the previously announced tender offer by Beta Acquisition Corp., a wholly-owned indirect subsidiary of Endo ("Merger Sub"), to acquire all of the outstanding shares of common stock, par value $0.001 per share (the "Shares") of BioSpecifics Technologies Corp. (Nasdaq: BSTC) ("BioSpecifics"), at a price of $88.50 per Share (the "Offer Price"), net to the holder in cash, without interest and less any applicable withholding taxes (the "Off

NEW YORK, Nov. 17, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY  10036(212) 682-3025(888) 593-4771[email protected] BioSpecifics Technologies Corp. (NASDAQ: BSTC) URGENT – TENDER OFFER EXPIRES DECEMBER 1, 2020 WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioSpecifics Technologies Corp. (NASDAQ: BSTC) in connection with the proposed acquisition of the company via tender offer by Endo

NEW YORK, Nov. 11, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of BSTC to Endo International plc for $88.50 per share. If you are a BSTC investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Cleveland BioLabs, Inc. (NASDAQ: CBLI) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger of CBLI with Cytocom whereby CBLI shareholders

NEW YORK, Nov. 10, 2020 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY  10036(212) 682-3025(888) 593-4771[email protected] BioSpecifics Technologies Corp. (NASDAQ: BSTC) URGENT – TENDER OFFER EXPIRES DECEMBER 1, 2020 WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioSpecifics Technologies Corp. (NASDAQ: BSTC) in connection with the proposed acquisition of the company by Endo International pl

WILMINGTON, Del., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating BioSpecifics Technologies Corp. (“BioSpecifics”) (NASDAQ GM: BSTC) regarding possible breaches of fiduciary duties and other violations of law related to BioSpecifics’ agreement to be acquired by Endo International plc (NASDAQ GS: ENDP). Under the terms of the agreement, BioSpecifics’ shareholders will receive $88.50 per share in cash. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-biospecifics-technologies-corp. You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or info@rl-legal.co

WILMINGTON, Del., Nov. 9, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) ("BioSpecifics" or the "Company"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced its financial results for the third quarter ended September 30, 2020.   "We believe the recently announced acquisition by Endo International plc marks a great outcome for all BioSpecifics stakeholders, and is the result of a successful value creation strategy. We trust that our long-time partner will serve as an excellent vehicle to advance and maximize the injectab

WILMINGTON, Del., Nov. 6, 2020 /PRNewswire/ -- Rigrodsky & Long, P.A. announces that it is investigating BioSpecifics Technologies Corp. ("BioSpecifics") (NASDAQ GS: BSTC) regarding possible breaches of fiduciary duties and other violations of law related to BioSpecifics' agreement to be acquired by Endo International plc (NASDAQ GS: ENDP).  Under the terms of the agreement, BioSpecifics' shareholders will receive $88.50 per share in cash. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-biospecifics-technologies-corp.    You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or [email protected]. Rig

NEW YORK, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Concho Resources Inc. (NYSE: CXO) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to ConocoPhillips. Under the terms of the merger, Concho shareholders will receive 1.46 shares of ConocoPhillips common stock for each share of Concho common stock they own. If you are a Concho shareholder, click on this link to learn more about your rights and options: https://halpersadeh.com/actions/concho-resources-inc-stock-merger-conocophillips. BioSpecifics Technologies Corp. (NASDAQ: BSTC) concerning pot

NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies: Telenav, Inc. (NASDAQ: TNAV) Telenav has agreed to be acquired by V99, Inc. Under the proposed transaction, shareholders of Telenav will receive $4.80 per share. Perceptron, Inc. (NASDAQ: PRCP) A proxy was recently filed with the SEC regarding Atlas Copco’s acquisition of Perceptron. Upo

NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of BSTC to Endo International plc for $88.50 per share. If you are a BSTC investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com. Cleveland BioLabs, Inc. (NASDAQ: CBLI) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger of CBLI with Cytocom whereby CBLI sha

NEW YORK, Nov. 4, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Endurance International Group Holdings, Inc. (NASDAQ: EIGI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to affiliates of Clearlake Capital Group L.P. for $9.50 per share in cash. If you are an Endurance International shareholder, click on this link to learn more about your rights and options: https://halpersadeh.com/actions/endurance-international-group-holdings-inc-eigi-stock-merger-clearlake/. Telenav, Inc. (NASDAQ: TNAV) concerning potential violations of the federal securities laws and/or

NEW YORK, Nov. 3, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioSpecifics Technologies Corp. ("BSTC" or the "Company") (NASDAQ: BSTC) in connection with the proposed acquisition of the Company by Endo International plc.  Under the terms of the acquisition agreement, which is structured as a tender offer, BSTC shareholders will receive $88.50 per share in cash for each share of BSTC that they hold.  If you own BSTC shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: https://www.weisslawllp.com/BSTC/ Or

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioSpecifics Technologies Corp. (NasdaqGS: BSTC) to Endo International plc (NasdaqGS: ENDP). Under the terms of the proposed transaction, shareholders of BioSpecifics will receive only $88.50 in cash for each share of BioSpecifics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your lega

NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies: BioSpecifics Technologies Corp. (NASDAQ: BSTC) A tender offer expiring on December 2nd was commenced by Endo International to acquire BioSpecifics Technologies for $88.50 per share.  The solicitation statements filed with the SEC in support of the acquisition may omit material information regar

NEW YORK, Oct. 30, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating BioSpecifics Technologies Corp. ("BioSpecifics" or the "Company") (BSTC) relating to its proposed acquisition by Endo International PLC. Under the terms of the agreement, BioSpecifics shareholders will receive $88.50 per share in cash. The investigation focuses on whether BioSpecifics Technologies Corp. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process and 2) whether and by ho

DUBLIN, Nov. 2, 2020 /PRNewswire/ -- Endo International plc (Nasdaq: ENDP) ("Endo") today announced that Endo's wholly-owned indirect subsidiary, Beta Acquisition Corp. ("Merger Sub"), has commenced its previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the "Shares") of BioSpecifics Technologies Corp. (Nasdaq: BSTC) ("BioSpecifics"), at a price of $88.50 per Share, net to the holder in cash, without interest and less any applicable withholding taxes (the "Offer"). The Offer is being made pursuant to the Agreement and Plan of Merger, dated October 19, 2020, by and among Endo, Merger Sub and BioSpecifics (as it may be amen

NEW YORK, Oct. 27, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of BSTC to Endo International plc for $88.50 per share. If you are a BSTC investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Cleveland BioLabs, Inc. (NASDAQ: CBLI) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger of CBLI with Cytocom whereby CBLI shareholders

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of BioSpecifics Technologies Corp. (NasdaqGS: BSTC) to Endo International plc (NasdaqGS: ENDP). Under the terms of the proposed transaction, shareholders of BioSpecifics will receive only $88.50 in cash for each share of BioSpecifics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your lega

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies: MyoKardia, Inc. (NASDAQ: MYOK) MyoKardia has agreed to be acquired by Bristol-Myers Squibb. Under the proposed transaction, shareholders of MyoKardia will receive $225.00 in cash per share owned. BioSpecifics Technologies Corp. (NASDAQ: BSTC) BioSpecifics Technologies has agree

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating BioSpecifics Technologies Corp. ("BioSpecifics" or the "Company") (BSTC) relating to its proposed acquisition by Endo International PLC. Under the terms of the agreement, BioSpecifics shareholders will receive $88.50 per share in cash. The investigation focuses on whether BioSpecifics Technologies Corp. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process and 2) whether and by ho

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Concho Resources Inc. (NYSE: CXO) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to ConocoPhillips. Under the terms of the merger, Concho shareholders will receive 1.46 shares of ConocoPhillips common stock for each share of Concho common stock they own. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/concho-resources-inc-stock-merger-conocophillips. Front Yard Residential Corporation (NYSE: RESI) concerning potential violations of the federa